********Firstly, many of the below questions have been answered a number of times.
There are 15 pts in the placebo of the 2 anemia trials- i would encourage you to look at the slides in the Company's presentation. These patients experienced no/minimal increase in Hgb despite even being on iron with a small std dev. No spa b/c it would have slowed down the trial design by months to try to negotiate one. The company is using 25 and 50 b/c of the protective effect of the endometrium as defined by the FDA as a need for consistency to back up the chronic fibroids trials and endo trials from a safety database perspective.
I suggest instead of insulting me with comments like Tony Snow/Bush, you actually get off your dead a** and read the previous answers to your questions and IF you are still not satisfied you should call/email the company for a response. It seems to me you are either lazy or want to keep posting questions for the sake of posting the same questions to create uncertainty.
----------------------------------------------------
Sounds just like Tony Snow interviewing Bush.
How about some real questions?
Why 15 patients in the palceboe arms of the 4 trials, especially when you know many will drop out?
Why no SPA?
The FDA does not like companies to use higher dosages than have been shown effective. For anemmia, why is the 15mg dose not in the P3?
What are the endpoints? In particular the company states the trials are 2.5X bigger than the P2s. So, this implies a composite endpoint of both arms treatment arms, or a P reduction. If composite, isn't that a danger in the fibr. trial? If a P reduction, what?
I know all these issues were beaten to death, so no need to ask. Just present the softballs.
AI
Market Data 
Markets 
